Evidence map›Paper›PMID 33879833›Full record

ArticleCommunications biology2021

Sensitive detection of SARS-CoV-2 seroconversion by flow cytometry reveals the presence of nucleoprotein-reactive antibodies in unexposed individuals.

Leire Egia-Mendikute, Alexandre Bosch, Endika Prieto-Fernández, So Young Lee, Borja Jiménez-Lasheras, Ana García Del Río, Asier Antoñana-Vildosola, Chiara Bruzzone, Maider Bizkarguenaga, Nieves Embade and 7 more

Open access · goldAbstract read
In one paragraph

Article in Communications biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Use of latex microbeads for detection of Plasmodium vivax lactate dehydrogenase using flow cytometry.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Leire Egia-Mendikute *Cancer Immunology and Immunotherapy Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia, Spain.ORCID 0000-0002-6435-1219
Alexandre Bosch *Cancer Immunology and Immunotherapy Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia, Spain.ORCID 0000-0002-3022-7463
Endika Prieto-FernándezCancer Immunology and Immunotherapy Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia, Spain.ORCID 0000-0001-8378-1495
So Young LeeCancer Immunology and Immunotherapy Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia, Spain.
Borja Jiménez-LasherasCancer Immunology and Immunotherapy Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia, Spain.
Ana García Del RíoCancer Immunology and Immunotherapy Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia, Spain.
Asier Antoñana-VildosolaCancer Immunology and Immunotherapy Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia, Spain.
Chiara BruzzonePrecision Medicine and Metabolism Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia, Spain.
Maider BizkarguenagaPrecision Medicine and Metabolism Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia, Spain.
Nieves EmbadePrecision Medicine and Metabolism Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia, Spain.
Rubén Gil-RedondoPrecision Medicine and Metabolism Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia, Spain.ORCID 0000-0002-3541-9085
María Luz Martínez-ChantarLiver Disease Laboratory, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia, Spain.
Marcos López-HoyosServicio Inmunología, Hospital Universitario Marqués de Valdecilla-IDIVAL, Facultad de Medicina, Universidad de Cantabria, Cantabria, Spain.
Nicola G A AbresciaCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0001-5559-1918
José M MatoPrecision Medicine and Metabolism Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia, Spain.ORCID 0000-0003-1264-3153
Óscar MilletPrecision Medicine and Metabolism Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia, Spain.
Asís PalazónCancer Immunology and Immunotherapy Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia, Spain. apalazon@cicbiogune.es.ORCID 0000-0002-7172-7229
CIC bioGUNE · ESIkerbasque · ESInstituto de Salud Carlos III · ESUniversidad de Cantabria · ES

Funding

EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 804236Ekonomiaren Garapen eta Lehiakortasun Saila, Eusko Jaurlaritza (Department of Industry, Innovation, Trade and Tourism, Basque Government) Bikaintek
6 · The paper itself

Abstract

There is an ongoing need of developing sensitive and specific methods for the determination of SARS-CoV-2 seroconversion. For this purpose, we have developed a multiplexed flow cytometric bead array (C19BA) that allows the identification of IgG and IgM antibodies against three immunogenic proteins simultaneously: the spike receptor-binding domain (RBD), the spike protein subunit 1 (S1) and the nucleoprotein (N). Using different cohorts of samples collected before and after the pandemic, we show that this assay is more sensitive than ELISAs performed in our laboratory. The combination of three viral antigens allows for the interrogation of full seroconversion. Importantly, we have detected N-reactive antibodies in COVID-19-negative individuals. Here we present an immunoassay that can be easily implemented and has superior potential to detect low antibody titers compared to current gold standard serology methods.

Indexed as

SeroconversionAntibodies, ViralAntigens, ViralCOVID-19Flow CytometryHumansImmunoassayImmunoglobulin GImmunoglobulin MNucleoproteinsPandemicsReproducibility of ResultsSARS-CoV-2Sensitivity and SpecificityAntibodies, ViralAntigens, ViralImmunoglobulin GImmunoglobulin MNucleoproteins

Identifiers

PMID33879833
PMCPMC8058339
OpenAlexW3155450006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.